Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-56356-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Lung Adenocarcinoma: Guiding EGFR-targeted Therapy and Beyond

Modern Pathology
Forensic MedicinePathology
2008English

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Disseminated Intravascular Coagulation in a Patient With Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Mutation Testing for Directing Upfront Targeted Therapy and Post-Progression Combination Therapy Strategies in Lung Adenocarcinoma

Expert Review of Molecular Diagnostics
Forensic MedicineGeneticsPathologyMolecular MedicineMolecular Biology
2016English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2008English

Salvage Surgery for Advanced Non-Small Cell Lung Cancer After Targeted Therapy: A Case Series

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Targeted T Cells for Anticancer Therapy

Science-Business eXchange
2009English

P1.13-28 the Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy